Format

Send to

Choose Destination
BMC Cancer. 2016 Jul 7;16:412. doi: 10.1186/s12885-016-2440-9.

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

Author information

1
Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France. a-adenis@o-lambret.fr.
2
Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000, Lille, France. a-adenis@o-lambret.fr.
3
Medical Oncology, Centre Léon Bérard, Lyon, France.
4
Medical Oncology, Paul Brousse University Hospital, Villejuif, France.
5
Medical Oncology, Gustave Roussy, Villejuif, France.
6
Gastroenterology, University Hospital, Poitiers, France.
7
Methodology and Biostatistics, Centre Oscar Lambret, Lille, France.
8
Medical Oncology, Clinique Sainte Anne, Strasbourg, France.
9
Medical Oncology, Hopital Privé des Côtes d'Armor, Plérin, France.
10
Radiation and Medical Oncology, Institut Sainte-Catherine, Avignon, France.
11
Clinical Research Unit, Centre Oscar Lambret, Lille, France.
12
Gastroenterology, University Hospital, Saint Etienne, France.
13
Medical Oncology, Saint Antoine Hospital, and University Pierre et Marie Curie (UMPC), Paris VI, Paris, France.

Abstract

BACKGROUND:

Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting.

METHODS:

REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival, safety, and potential prognostic factors for outcome associated with regorafenib in patients with mCRC refractory to standard therapies. Treatment effects according to various patient and tumour characteristics were evaluated using univariate and multivariate Cox proportional hazards regression models.

RESULTS:

Of 1178 patients in the compassionate use program, 654 were in the full analysis set. Median follow-up was 16.5 months. Median survival was 5.6 months. The 12-month survival rate was 22 %. Survival was independently and unfavourably affected by the following variables: poor performance status, short time from initial diagnosis of metastases to the start of regorafenib, low initial regorafenib dose, >3 metastatic sites, presence of liver metastases, and KRAS mutations. We identified prognostic groups of patients with low, intermediate, and high risk of death, with a median survival of 9.2, 5.2, and 2.5 months, respectively. Five-hundred-twenty-four patients (80 %) experienced at least one regorafenib-related adverse event, most commonly, fatigue, hand-foot skin reaction, diarrhea, anorexia, arterial hypertension, and mucositis.

CONCLUSION:

The safety and efficacy profile of regorafenib in REBECCA are similar to those in randomized trials. Our prognostic model identified subgroups of mCRC patients who derived a minimal and maximum benefit from regorafenib.

TRIAL REGISTRATION:

Clinicaltrials.gov NCT02310477 .

KEYWORDS:

Antiangiogenic; Cohort study; Colorectal cancer; Metastatic disease; Regorafenib

PMID:
27389564
PMCID:
PMC4936193
DOI:
10.1186/s12885-016-2440-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center